F. Oury-Donat

发表

SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome

C. Wermuth, P. Soubrié, R. Boigegrain, 2005, Psychopharmacology.

The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics

B. Scatton, F. Oury-Donat, G. Le Fur, 2022 .

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile

G. Griebel, O. Bergis, L. Rouquier, 2007, Neuropsychopharmacology.

Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

P. Soubrié, B. Scatton, F. Oury-Donat, 2007, Hepatology.

SR120819A, an orally‐active and selective neuropeptide Y Y1 receptor antagonist

F. Oury-Donat, J. Maffrand, G. Néliat, 1995, FEBS letters.

The Cannabinoid CB 1 Receptor Antagonist Rimonabant ( SR 141716 ) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3 T 3 F 442 A Preadipocytes

B. Scatton, F. Oury-Donat, G. Fur, 2006 .

Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.

J. Simiand, P. Soubrié, P. Casellas, 1993, European journal of pharmacology.

SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}- 4-piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor: I. Biochemical and Pharmacological Characterization

P. Soubrié, R. Steinberg, F. Oury-Donat, 2002, Journal of Pharmacology and Experimental Therapeutics.

Characterization of CB1 Receptors on Rat Neuronal Cell Cultures: Binding and Functional Studies Using the Selective Receptor Antagonist SR 141716A

P. Soubrié, F. Oury-Donat, M. Rinaldi-Carmona, 1997, Journal of neurochemistry.

Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells.

P. Soubrié, F. Oury-Donat, O. Thurneyssen, 1995, The Journal of pharmacology and experimental therapeutics.

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.

P. Soubrié, M. Poncelet, C. Gueudet, 2002, Canadian journal of physiology and pharmacology.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

P. Soubrié, D. Gully, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

SR 140333, a Novel, Selective, and Potent Nonpeptide Antagonist of the NK1 Tachykinin Receptor: Characterization on the U373MG Cell Line

P. Soubrié, A. Bordey, F. Oury-Donat, 1994, Journal of neurochemistry.

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia

G. Griebel, J. Stemmelin, O. Bergis, 2007, Neuropsychopharmacology.

Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic

R. Depoortère, G. Perrault, G. Griebel, 2005, Neuropsychopharmacology.

Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.

G. Griebel, P. Soubrié, M. Poncelet, 2001, Journal of Pharmacology and Experimental Therapeutics.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

P Ferrara, P. Soubrié, P. Casellas, 1998, European journal of pharmacology.

Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non‐neuronal cells

P. Soubrié, D. Gully, F. Oury-Donat, 1995, British journal of pharmacology.

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

G. Griebel, J. Stemmelin, D. Boulay, 2008, Pharmacology Biochemistry and Behavior.

2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission

R. Steinberg, F. Oury-Donat, J. Souilhac, 2006, Neuroscience.

Effects of the β3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: Relevance to its antidepressant/anxiolytic-like profile

Y. Claustre, L. Rouquier, B. Scatton, 2008, Neuroscience.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

P. Soubrié, F. Oury-Donat, J. Maffrand, 2003, Molecular pharmacology.

Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor.

F. Oury-Donat, F. Barth, G. Tamagnan, 2014, Bioorganic & medicinal chemistry letters.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

P. Soubrié, D. Gully, R. Boigegrain, 1997, The Journal of pharmacology and experimental therapeutics.

Expression of tachykinin NK2 receptor mRNA in human brain

P. Soubrié, E. Hirsch, Y. Agid, 2001, Neuroscience Letters.

Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.

J. Simiand, P. Soubrié, F. Oury-Donat, 1993, Molecular pharmacology.

Expression and presence of septal neurokinin‐2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat

P. Soubrié, R. Steinberg, F. Oury-Donat, 1998, The European journal of neuroscience.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

P. Soubrié, S. Galiègue, P. Casellas, 2002, Molecular pharmacology.

Effects of the vasopressin (V1B) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat

Y. Claustre, L. Rouquier, R. Steinberg, 2006, Neuroscience.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

P. Soubrié, D. Gully, R. Boigegrain, 1997, The Journal of pharmacology and experimental therapeutics.